Jazz Pharmaceuticals v. Apotex, Lupin & Others — Cannabidiol Oral Solution Patent Litigation
Jazz Pharmaceuticals Research UK Limited filed suit in the District of New Jersey against ten generic pharmaceutical defendants, asserting two patents covering a cannabidiol 100 mg/mL oral solution. Claims against Lupin Ltd. were dismissed without prejudice by stipulation after 270 days, while claims against the remaining defendants continue.
Jazz targets ten generics in cannabidiol formulation patent dispute
On 15 December 2023, Jazz Pharmaceuticals Research UK Limited filed an infringement action in the U.S. District Court for the District of New Jersey against ten generic pharmaceutical defendants — including Apotex, Lupin, Cipla, Taro, MSN, InvaGen, Biophore, API Pharma Tech, Ascent, and Zenara — asserting U.S. Patent Nos. 11,701,330 and 11,865,102, both covering a cannabidiol 100 mg/mL oral solution. The case is consistent with standard Hatch-Waxman ANDA litigation patterns, in which a branded pharmaceutical company moves to block generic market entry.
On 10 September 2024 — 270 days after filing — Jazz and Lupin Ltd. filed a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), dismissing all claims, counterclaims, and affirmative defenses between those two parties without prejudice and without costs. Critically, the stipulation explicitly preserves all claims against the remaining nine defendants and retains district court jurisdiction to enforce any future disputes between Jazz and Lupin relating to the same subject matter.
The without-prejudice dismissal as to Lupin after nine months suggests the parties may have reached a confidential licensing or settlement arrangement, though the public record is silent on any terms. Early bilateral resolution in multi-defendant ANDA cases of this scale is not uncommon and may reflect Lupin’s commercial position or patent challenge strategy. The case remains active against the other defendants, meaning Jazz’s enforcement campaign over these cannabidiol formulation patents is far from resolved.
Filing to Dismissed without Prejudice in 270 days
270 days from filing to partial dismissal — typical ANDA litigation runs 2–4 years to trial
Without-prejudice dismissal as to Lupin: what the stipulation means
Rule 41(a)(1)(A)(ii) stipulated dismissal — no merits adjudicated
A dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) requires written consent from all parties to the stipulation. No court finding on infringement or patent validity is made — the case simply ends as between the stipulating parties. The without-prejudice designation means Jazz retains the right to refile claims against Lupin in the future, and no res judicata bar attaches to the dismissed claims.
No merits rulingWithout prejudice means Jazz can refile against Lupin at any time
Because the dismissal is without prejudice, Jazz preserves the right to reassert US11701330B2 and US11865102B2 against Lupin if circumstances change — for example, if Lupin seeks FDA approval for a modified formulation or if any underlying agreement between the parties breaks down. The district court expressly retains jurisdiction to resolve disputes between Jazz and Lupin on the same subject matter, suggesting ongoing obligations between the parties are likely.
Refiling right preservedNine defendants remain — Jazz’s enforcement action is ongoing
The stipulation explicitly states that Jazz’s dismissal of claims against Lupin does not affect any claims, defenses, or counterclaims against any other defendant. Apotex, Cipla, Taro, MSN, InvaGen, Biophore, API Pharma Tech, Ascent, and Zenara all remain active parties. For those defendants, patent validity and infringement questions remain live and unresolved, maintaining full litigation risk.
Case continues vs. nine othersEarly bilateral exit may signal confidential terms with Lupin
Voluntary early dismissal without prejudice and without costs in multi-defendant ANDA litigation typically suggests a confidential licensing, settlement, or market-entry agreement between the parties — though the public record here is silent. If a consent judgment or license was agreed, Lupin’s ANDA timeline may be commercially defined. Patent professionals should monitor FDA Orange Book listings and any future filings between these parties for indirect signals.
Likely confidential arrangementFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Jazz Pharmaceuticals Research UK Limited | Individual | Branded pharmaceutical IP licensor — holder of US11701330B2 and US11865102B2Search in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | Generic pharmaceutical manufacturers seeking to commercialise cannabidiol oral solutionSearch in Eureka ↗ |
| Co-Defendant | API Pharma Tech, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Biophore Pharma, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Invagen Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Others too numerous to list: CIPLA USA, INC., ASCENT PHARMACEUTICALS, INC. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Taro Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Cipla Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Zenara Pharma Private, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Jazz Pharmaceuticals Research UK LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Jazz Pharmaceuticals Research UK LimitedSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Jazz Pharmaceuticals Research UK LimitedSearch in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Jazz Pharmaceuticals Research UK LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Jazz Pharmaceuticals Research UK LimitedSearch in Eureka ↗ |
| Defendant counsel | Melissa Ellen Flax | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant law firm | Carella Byrne Cecchi Olstein Brody & Agnello, PC | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation is surgical in scope: it resolves only the Jazz–Lupin bilateral dispute, leaving the broader multi-defendant infringement action entirely intact. The express carve-out — ‘dismissal of these matters with respect to Lupin shall not result in the dismissal of any claims, defenses, and/or counterclaims with respect to any other defendant’ — forecloses any argument that the Lupin exit weakens Jazz’s enforcement posture against the remaining nine defendants. The court’s retained jurisdiction clause is consistent with a structured exit that anticipates future compliance monitoring.
US11701330B2 & US11865102B2 — Cannabidiol 100 mg/mL Oral Solution
US11701330B2 and US11865102B2 both relate to pharmaceutical formulations of cannabidiol (CBD) as a 100 mg/mL oral solution — the concentration associated with FDA-approved prescription cannabidiol products for epilepsy indications. The applications (US17/472016 and US17/529005) were filed in 2021 and 2021–2022 respectively, placing them in a competitive post-approval filing window as branded manufacturers sought to extend formulation protection beyond the core API patent estate.
For the cannabidiol pharmaceutical sector, these patents represent a formulation-layer enforcement strategy: protecting specific concentration, excipient, and stability characteristics rather than the API itself. This is commercially significant because generic ANDA applicants must address formulation patents even where the cannabidiol molecule is off-patent. Any company developing a CBD oral solution at 100 mg/mL faces direct infringement exposure under these grants until they are invalidated, licensed, or expire.
Should your cannabidiol oral solution ANDA address US11701330B2 and US11865102B2?
Any pharmaceutical company, CDMO, or API supplier involved in the development or commercialisation of a cannabidiol 100 mg/mL oral solution should treat these two patents as primary FTO hurdles. The active multi-defendant litigation — with nine defendants still named — confirms Jazz is prepared to enforce both grants aggressively. Even companies not yet named in this action should assess whether their formulation specifications or manufacturing process could fall within the asserted claims.
PatSnap Eureka’s FTO Search Agent can map the claims of US11701330B2 and US11865102B2 against your specific formulation parameters, flag prior art that could support invalidity arguments, and monitor for new continuations or divisionals in Jazz’s cannabidiol patent family. Real-time docket alerts on this case will flag any claim construction orders or invalidity rulings that could reshape the FTO landscape for all remaining defendants.
Run a freedom-to-operate analysis on US11701330B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabidiol and pharmaceutical formulation ANDA cases in New Jersey
These cases involve comparable cannabidiol or pharmaceutical oral solution formulation patents litigated under the Hatch-Waxman framework in the District of New Jersey.
What this case signals for the cannabidiol pharmaceutical IP landscape
Jazz’s multi-defendant ANDA campaign over cannabidiol oral solution patents illustrates how branded pharma defends formulation IP against a wave of generics.
Multi-defendant ANDA filings concentrate enforcement risk — track each defendant separately
With ten defendants named simultaneously, Jazz’s litigation strategy is designed to impose maximum cost and uncertainty on the generic market. Early resolution with one defendant (Lupin) does not reduce risk for the others. IP teams at any company with an ANDA for cannabidiol oral solution should treat this case as an active enforcement threat regardless of the Lupin dismissal.
Without-prejudice exits in ANDA cases often precede Orange Book license disclosures
When a branded company and a generic settle ANDA litigation without prejudice, regulatory watchers should monitor Orange Book patent certifications and any ANDA approval dates for indirect evidence of licensing terms. The district court’s retained jurisdiction clause is a further signal that ongoing contractual obligations likely govern the Jazz–Lupin relationship beyond this docket.
Limited v Apotex — key questions answered
Jazz Pharmaceuticals Research UK Limited asserted U.S. Patent Nos. 11,701,330 (application US17/472016) and 11,865,102 (application US17/529005), both covering a cannabidiol 100 mg/mL oral solution, against ten generic pharmaceutical defendants in the District of New Jersey.
Jazz and Lupin filed a stipulated dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) on 10 September 2024, dismissing all claims between them without prejudice and without costs. The public record does not disclose the reason, but without-prejudice dismissals in ANDA cases of this type typically suggest a confidential licensing or settlement arrangement.
No. The stipulation expressly states that Jazz’s dismissal of claims against Lupin does not affect any claims, defenses, or counterclaims with respect to any other defendant. Apotex, Cipla, Taro, MSN, InvaGen, Biophore, API Pharma Tech, Ascent, and Zenara remain active defendants.
Yes. A dismissal without prejudice does not bar refiling — no res judicata effect attaches. Additionally, the stipulation expressly states that the District of New Jersey retains jurisdiction to enforce and resolve disputes between Jazz and Lupin relating to the subject matter of the dismissed actions, consistent with ongoing obligations between the parties.
The product at issue is a cannabidiol 100 mg/mL oral solution. This concentration corresponds to the formulation associated with FDA-approved prescription cannabidiol products for epilepsy. The litigation is consistent with standard Hatch-Waxman ANDA enforcement by the branded manufacturer to prevent generic market entry.
PatSnap Eureka searches patents and litigation data to answer instantly.